PDCD1 and neoplasm: In summary, presurgical PD-1 blockade seems to induce local and systemic immune responses, with enhanced priming and expansion of tumor-specific T cells, probably driven by tumor-associated-antigens exposure and prolonged in subsequent adjuvant doses.